Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

Related Experiment Video

Updated: Mar 11, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.0K

M K van der Kooij1, A Joosse1, F M Speetjens1

  • 1a Department of Clinical Oncology , Leiden University Medical Center , Leiden , The Netherlands.

Acta Oncologica (Stockholm, Sweden)
|December 3, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
06:46

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Published on: September 4, 2021

1.9K

Related Experiment Videos

Last Updated: Mar 11, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.0K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
06:46

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Published on: September 4, 2021

1.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Long-term quality of life and physical functioning after curative local treatment of colorectal metastases in older patients.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trial.

BMC cancer·2026

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

European journal of cancer (Oxford, England : 1990)·2025

Metastatic mismatch repair deficient oesophageal squamous cell carcinoma leading to diagnosis of Lynch syndrome with a complete response to nivolumab treatment.

Virchows Archiv : an international journal of pathology·2025

Cross-sectional study of long-term Health-Related Quality of Life in stage III melanoma patients receiving neo-adjuvant versus adjuvant immune checkpoint inhibitors.

European journal of cancer (Oxford, England : 1990)·2025

Treatment attrition and outcomes of myeloma patients in Finland: a real-world study.

Acta oncologica (Stockholm, Sweden)·2026

Detection of circulating tumor HPV-DNA in patients with HPV-positive sinonasal and nasopharyngeal carcinoma.

Acta oncologica (Stockholm, Sweden)·2026

Continuous intrathecal therapy for refractory cancer pain: A systematic review and meta-analysis focusing on partially implanted devices.

Acta oncologica (Stockholm, Sweden)·2026

Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.

Acta oncologica (Stockholm, Sweden)·2026

Tools for providing information to patients about high-tech medical resources for treatment of cancer.

Acta oncologica (Stockholm, Sweden)·2026

Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study.

Acta oncologica (Stockholm, Sweden)·2026

Hypothesis-generating network toxicology analysis of potential molecular convergence between a polystyrene oligomer proxy and papillary thyroid carcinoma.

Frontiers in endocrinology·2026

Practice patterns in myeloma bone disease: a multi-center survey.

Frontiers in oncology·2026

Benefit-risk profiling of advanced therapies in moderate-to-severe ulcerative colitis: a clustered network meta-analysis.

Frontiers in pharmacology·2026

Efficacy and safety of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer after EGFR-TKI resistance: a systematic review and meta-analysis.

Frontiers in oncology·2026

Blockade of the calpain-1/HSP90/TGF-β1 axis by Astragaloside IV ameliorates bleomycin-induced pulmonary fibrosis.

Frontiers in pharmacology·2026

Genomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations.

Cancer medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us